The patent of TMB-365 with LM52 Glycan Modification technology has already been granted by the United States, Japan, Germany, the United Kingdom, France, Spain, Italy, China, Taiwan, and other countries.
This time, the United States Patent and Trademark Office granted the patent on the use of histidine modification technology to enhance the pharmacokinetic performance of TMB-365, following approvals from the Japan and Taiwan patent offices.
The patent uses Histidine Modification engineering technology to improve the pharmacokinetic performance of TMB-365. Prolonging its blood half-life will eventually allow TMB-365 to maintain its effective drug blood concentration for a longer period, making it a long-acting monoclonal antibody drug. Patent applications have been filed in major countries or regions worldwide, and the patent protection period can be until 2040.